Bradley Todd, Grundberg Elin, Selvarangan Rangaraj
medRxiv. 2021 Feb 5:2021.02.03.21251078. doi: 10.1101/2021.02.03.21251078.
Current guidelines recommend that individuals who have had COVID-19 should receive the identical vaccine regimen as those who have not had the infection. This includes two doses of the mRNA platform vaccines (BNT162b2/Pfizer; mRNA-1273/Moderna) that are approved for use in the United States. In this brief report, we show that after a single dose of the Pfizer SARS-CoV-2 vaccine, individuals that had prior SARS-CoV-2 infection had significantly higher antibody levels than individuals that had no history of infection. This provides the rationale for changing vaccination policy to deliver only a single dose to individuals with recent SARS-CoV-2 infection that may free up additional doses for individuals that have no preexisting immunity to the virus. Future study of other immune parameters such as T cell response and durability of immune response should be rapidly undertaken in individuals that had COVID-19 prior to vaccination.
当前指南建议，感染过新冠病毒的个体应接种与未感染过的个体相同的疫苗方案。这包括两剂已在美国获批使用的mRNA平台疫苗（BNT162b2/辉瑞；mRNA-1273/莫德纳）。在本简短报告中，我们表明，在接种一剂辉瑞新冠病毒疫苗后，既往感染过新冠病毒的个体的抗体水平显著高于无感染史的个体。这为改变疫苗接种政策提供了理论依据，即仅向近期感染过新冠病毒的个体接种一剂疫苗，这可能会为对该病毒无预先免疫力的个体腾出更多剂量。对于接种疫苗前感染过新冠病毒的个体，应迅速开展对其他免疫参数（如T细胞反应和免疫反应持久性）的进一步研究。
